Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0C9FF
|
|||
Former ID |
DCL000776
|
|||
Drug Name |
DNK-333
|
|||
Synonyms |
DNK 333; DNK333; N-((R,R)-(E)-1-(3,4-Dichlorobenzyl)-3-(2-oxoazepan-3-yl)carbamoyl)allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Irritable bowel syndrome [ICD-11: DD91.0; ICD-10: K58.0] | Discontinued in Phase 2 | [1] | |
Company |
Novartis
|
|||
Structure |
Download2D MOL |
|||
Formula |
C27H25Cl2F6N3O3
|
|||
Canonical SMILES |
CN(C(CC1=CC(=C(C=C1)Cl)Cl)C=CC(=O)NC2CCCCNC2=O)C(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
|
|||
InChI |
1S/C27H25Cl2F6N3O3/c1-38(25(41)16-12-17(26(30,31)32)14-18(13-16)27(33,34)35)19(10-15-5-7-20(28)21(29)11-15)6-8-23(39)37-22-4-2-3-9-36-24(22)40/h5-8,11-14,19,22H,2-4,9-10H2,1H3,(H,36,40)(H,37,39)/b8-6+/t19-,22+/m0/s1
|
|||
InChIKey |
BHCJHYIMNHXLOM-WVDRJWPYSA-N
|
|||
CAS Number |
CAS 398507-81-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Substance-K receptor (TACR2) | Target Info | Modulator | [2] |
Substance-P receptor (TACR1) | Target Info | Modulator | [2] | |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Measles | ||||
Panther Pathway | CCKR signaling map ST | |||
Reactome | G alpha (q) signalling events | |||
WikiPathways | SIDS Susceptibility Pathways | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Spinal Cord Injury | ||||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | |||
REF 2 | Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J. 2004 Jan;23(1):76-81. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.